Lonza
Münchensteinerstrasse 38, Basel, Basel-Stadt, 4052, Switzerland
Overview
Lonza Group AG, a Life Sciences driven chemical company, supplies active ingredients, chemical intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries. The company also offers a catalogue of organic intermediates for a range of applications, such as pharmaceuticals, agrochemicals, vitamins, food and feedstuff, dyes and pigments, adhesives and fragrances. It also manufactures specialty biocides and oleochemicals; and develops and produces specific polymer intermediates, unsaturated polyester-resins, compounds and composites. The company operates in three divisions that include Exclusive Synthesis & Biopharmaceuticals; Organic Fine & Performance Chemicals; and Polymer Intermediates. Exclusive Synthesis & Biopharmaceuticals In the area of Exclusive Synthesis and Biopharmaceuticals, Lonza is the custom manufacturing for the global life sciences companies. In addition to Lonza's traditional chemical custom manufacturing, Lonza offers microbial custom fermentation and biotransformation services. Lonza Biologics is focused on the production of therapeutic monoclonal antibodies and recombinant proteins produced by mammalian cell cultures. Exclusive chemical synthesis: Exclusive chemical synthesis engages in the process development and manufacture of intermediates and active ingredients. It is used in Life sciences industry, pharmaceuticals and animal health products. Exclusive microbial fermentation and biotransformation: Exclusive microbial fermentation and biotransformation processes development and manufactures intermediates, active ingredients and biopharmaceuticals. Its products are used Life sciences industry, pharmaceuticals and cosmetics. The company also offers L-Carnitine (L-Carnipure), which is applicable in sports nutrition, food, pharmaceuticals and feedstuffs. Exclusive microbial biopharma fermentation: Exclusive microbial biopharma fermentation engages in the process development and manufacture of therapeutic recombinant proteins and antibody fragments. It is used in pharmaceutical and biotechnology industry. Exclusive mammalian cell fermentation: Exclusive mammalian cell fermentation engages in the process development and manufacture of therapeutic monoclonal antibodies and recombinant proteins, proprietary GS-expression system, which are used in the pharmaceutical and biotechnology industry. Organic Fine & Performance Chemicals In the area of organic fine and performance chemicals, the company develops, manufactures, and sells various organic chemical intermediates applied in pharmaceuticals, agrochemicals, vitamins, food and feed, dyes, pigments, adhesives, and fragrances, as well as polymers. The sector performance chemical is mainly engaged in the development and production of biocides and oleochemicals. These core activities are supplemented by the polymer intermediates business, including additives, unsaturated polyester resins, compounds, and composites. Organic Fine Chemicals: The company offers Niacin, niacinamide, Diketene derivatives, Hydrocyanic acid derivatives, Engineering polymer additives and Meta – Metaldehyde. Its products are used in food and feedstuffs, pharmaceuticals, agrochemicals, colorants Vitamins, optical brighteners, agrochemicals, electronics, aerospace industry, and coating Snail. Performance Chemicals: The company offers microbiologically active substances, such as Quaternary ammonium, compounds, Halogenated hydantoins; and Hydantoin derivatives. It also offers Oleochemical derivatives. The company's products are used by the disinfectants for household, industrial and institutional applications, including water treatment and wood preservation; biocides for water treatment, pools and spas, and household disinfection; preservatives for personal care and household products; and food ingredients, humectants and emollients for personal care, processing aids and lubricants for polymer and textile industry, and industrial defoamers.
- Total investments
- 4
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Biotechnology
- Life Science
- Pharmaceutical
Investment portfolio
- Indapta Therapeutics
Participated · Series A · Feb 2022
Indapta Therapeutics is a clinical-stage biotechnology company developing differentiated allogeneic natural killer (g-NK) cell therapies for blood and solid-tumor cancers and autoimmune diseases. Its lead candidate, IDP-023, has completed enrollment in the safety run-in portion of a Phase 1 trial in Non-Hodgkin’s Lymphoma and Multiple Myeloma. In responding myeloma patients the mean maximum decrease in serum M-protein or light chain was 73%, with three patients showing reductions of 84% or greater. Cohorts testing IDP-023 in combination with monoclonal antibodies targeting CD20 or CD38 are currently enrolling. The company secured FDA clearance of an IND to study IDP-023 with ocrelizumab in progressive multiple sclerosis and plans to initiate a Phase 1 MS trial in Q1 2025. Indapta’s proprietary g-NK platform is described as offering multiple mechanisms—enhancing B-cell depletion with antibodies, targeting HLA-E upregulated autoreactive cells, and potentially addressing EBV reservoirs—and the company recently announced a collaboration with Sanofi. It closed a $22.5 million financing to accelerate these clinical development programs. Indapta Therapeutics is a privately held biotechnology company developing a universal, allogeneic NK cell therapy platform based on G-NK cells to treat multiple types of blood cancers and solid tumors. Its G-NK cells are FcεRIγ-deficient, isolated from healthy donors, not genetically engineered, and exhibit increased antibody-dependent cellular cytotoxicity compared with conventional NK cells. Indapta has enhanced G-NK cells through subset selection and a proprietary manufacturing process to produce a banked, off-the-shelf product with reportedly higher efficacy, persistence and improved cryopreservation; in vivo studies have demonstrated safety and efficacy. The company is partnering with Lonza for process development and cGMP manufacturing to support clinical supply. Proceeds from the recent financing will be used to grow the team and advance the G-NK platform toward an IND and clinical trials. Indapta was founded in 2017 based on a discovery at UC Davis, with scientific founders Sungjin Kim and John Sunwoo.
- Affinia Therapeutics
Participated · Series B · May 2021
Affinia Therapeutics engineers novel adeno-associated virus (AAV) capsids to create gene therapies that more selectively target heart and skeletal muscle while reducing liver exposure. Its lead candidate, AFTX-201, employs a proprietary cardiotropic capsid to deliver a fully human BAG3 transgene for the treatment of BAG3 dilated cardiomyopathy (DCM), a life-threatening inherited heart disease affecting more than 70,000 patients across the U.S., Europe and the U.K. Preclinical studies showed that AFTX-201 restored cardiac function in animal models where conventional capsids failed at the same dose. The company plans to submit an IND for AFTX-201 in Q4 2025 and, pending FDA acceptance, begin a Phase 1/2 UPBEAT trial in Q1 2026. Affinia’s generative-AI discovery platform is also being applied to build a broader pipeline of gene therapies for additional devastating cardiovascular and neurological indications. The newly announced $40 million Series C financing extends the company’s runway to support these clinical and pipeline milestones.
- ConnectedYard (pHin)
Participated · Series A · Dec 2016
ConnectedYard provides the pHin, a smart water care solution that combines a Bluetooth- and WiFi-enabled water monitor with a mobile app for pool and hot tub care. Led by co-founder and CEO Justin Miller, the company focuses on Internet of Things (IoT) pool care products. ConnectedYard closed a $7M Series A financing to accelerate investment in its technology. The company intends to use the funds to grow its customer base and scale the business. It plans to expand into everyday components involved in outdoor living. Lonza, one of the Series A backers, will become ConnectedYard’s strategic market partner. ConnectedYard develops Internet of Things technology and smart water solutions for pools and hot tubs. Its core product, pHin, pairs a Bluetooth Smart and WiFi-enabled sensor with a mobile app to continuously monitor water quality 24/7 and send automatic alerts when chemicals are needed. pHin is offered as a subscription that includes shipments of pre-measured, water-soluble, color-coded chemical pods. The subscription also provides access to a network of on-demand, qualified pool service technicians. The company was co-founded by COO Mark Janes and CEO Justin Miller. ConnectedYard closed $2.2M in seed funding.